Buzz: If it’s an Irish biopharma company, it’s on analysts’ M&A list

John Carroll Ireland-based biopharma companies are all the rage these days. Blessed by advantageous tax laws, Elan and Warner Chilcott fell to takeover bids. And now that Jazz Pharmaceuticals ...

Who will be first of 2014 to be bought? Some say Jazz

Eric Palmer Industry analysts can't help but handicap which drugmakers will be the next target of heated industry M&A interest. So three days into the new year, they are putting ...

Sanofi is allowing open access from Jan. 1 on out

Carly Helfand Following in the footsteps of Big Pharma counterparts like GlaxoSmithKline, Sanofi says it will provide data, documents and reports on studies used to support U.S. and ...

AstraZeneca buys a CDK9 cancer drug portfolio

John Carroll AstraZeneca has swooped in to pick up a portfolio of new cancer therapy from Germany's Probiodrug. The pharma giant paid an undisclosed sum for the biotech's CDK9 ...

Giving letter grades for 2013 pharma performance

Eric Palmer Anyone can judge drugmakers' annual results by the numbers: top line, bottom line, growth, earnings or some combination of financial markers. It's more daring to ...

Google Ventures backs DNAnexus’ $15M round for R&D cloud platform

John Carroll Google Ventures has joined a group of investors seeding DNAnexus' cloud-computing services for biomedical researchers with a $ 15 million C round. FierceBiotech News

J&J seeks court’s blessing to make Doxil at closed Ben Venue facility

Eric Palmer Janssen and Ben Venue officials have assured a federal court that any operations Janssen initiates at Ben Venue's now-closed Ohio facility will comply with provisions ...

Buzz: A buyer is in talks to acquire a big stake in Celltrion

John Carroll The buzz about the potential sale of a big stake in Celltrion, Korea's biosimilars developer, picked up after the company filed a statement with regulators indicating ...

Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M

Eric Palmer Merck early in December agreed to sell the rights to its antipsychotic drug Saphris to Forest Laboratories for $ 240 million. The move not only gave it a small cash boost, ...

Third Rock’s Eleven pitches a $69M IPO to fuel its PhIII dry eye program

John Carroll A little less than four years after Third Rock and Flagship joined forces and investment cash to back the launch of Eleven Biotherapeutics, the protein engineering company ...
Page 5 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS